Business Context and Reporting Period
Cytosorbents Corporation (CTS) filed a Form 8-K on May 12, 2020, reporting a significant regulatory milestone. The Company is a Delaware corporation with its principal executive offices in Monmouth Junction, New Jersey, and its common stock trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material change reported is the regulatory approval of the Company's CytoSorb® device in the European Union. Specifically, the device is approved for the removal of rivaroxaban (Xarelto®), a Factor Xa inhibitor and novel oral anticoagulant, during cardiothoracic surgery requiring cardiopulmonary bypass. The product is immediately available in the EU for this indication.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the announcement of the approval. The event is categorized under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the specific scope of the EU approval for rivaroxaban removal during cardiothoracic surgery.
- Confirm the commercial availability timeline and distribution strategy for CytoSorb® in the European Union.
- Review the attached press release (Exhibit 99.1) for details on the clinical data supporting the approval.
- Assess the potential revenue impact of this new indication relative to the Company's overall product portfolio.